Page 14 - Genmark Diagnostics News Today : Breaking News, Live Updates & Top Stories | Vimarsana

MedTech industry news

Get the latest industry news first when you subscribe to our daily newsletter. We will never sell or share your information without your consent. See our privacy policy.

Molecular Diagnostics Market worth $31.8 billion by 2026 - Exclusive Report by MarketsandMarkets "Molecular Diagnostics Market by Product & Service(Reagents, Kits, PoC & Tabletop Instruments), Application(COVID-19, Hepatitis, HAI, HIV, Oncology, Genetic Tests), Technology (PCR, NGS, ISH), End User (Hospitals, Diagnostic Labs) - Global Forecast to 2026", published by MarketsandMarkets, the global market is projected to reach USD 31.8 billion by 2026 from USD 17.8 billion in 2021, at a 12.3% CAGR. Browse in-depth TOC on Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.a...

)  WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Extended Stay America, Inc. (NASDAQ: STAY) in connection with the proposed acquisition of the company and its paired-share REIT, ESH Hospitality, Inc., by funds managed by Blackstone Real Estate Partners and Starwood Capital Group. Under the terms of the merger agreement, STAY shareholders will receive $19.50 in cash for each share of STAY common stock that they hold. If you own STAY shares and wish to discuss this investigation or your rights, please call us or vi...

Home / Top News / GENMARK ALERT: Bragar Eagel & Squire, P.C. Investigates Recently Announced Tender Offer for GNMK and Encourages Investors to Contact the Firm GENMARK ALERT: Bragar Eagel & Squire, P.C. Investigates Recently Announced Tender Offer for GNMK and Encourages Investors to Contact the Firm NEW YORK, March 31, 2021 (GLOBE NEWSWIRE) — Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, advises that a tender offer to acquire GenMark Diagnostics, Inc. (NASDAQ: GNMK) has commenced and reminds investors that the firm is investigating whether GenMark’s of...